Remission induction in acute myeloid leukemia Journal Article

   


Authors: Stein, E. M.; Tallman, M. S.
Article Title: Remission induction in acute myeloid leukemia
Abstract: Inducing a complete remission (CR) in patients with acute myeloid leukemia is a prerequisite to long-term disease control with subsequent post-remission consolidation chemotherapy or allogeneic hematopoietic stem cell transplantation. The use of 7 days of infusional cytarabine and 3 days of daunorubicin or idarubicin (7 ± 3) has become the standard of care to induce CR, based on clinical trials conducted in the 1980s. Efforts to improve on the CR rate seen with the 7 ± 3 regimen that translates into better overall patient survival have been disappointing. Here we review recent phase III studies of novel induction strategies that show promise in increasing the rate of CR and improving disease outcome. © 2012 The Japanese Society of Hematology.
Keywords: cancer chemotherapy; event free survival; treatment outcome; treatment response; acute granulocytic leukemia; gene mutation; overall survival; leukemia, myeloid, acute; fludarabine; neutropenia; erlotinib; drug dose comparison; monotherapy; side effect; unspecified side effect; cytarabine; drug megadose; clinical practice; low drug dose; liver toxicity; multiple cycle treatment; blood toxicity; thrombocytopenia; antineoplastic combined chemotherapy protocols; combination chemotherapy; cytogenetics; continuous infusion; drug fatality; cardiotoxicity; gefitinib; daunorubicin; remission; remission induction; sepsis; idarubicin; drug dose increase; heart left ventricle ejection fraction; gemtuzumab ozogamicin; cladribine; leukemia remission; acute myeloid leukemia; cancer prognosis
Journal Title: International Journal of Hematology
Volume: 96
Issue: 2
ISSN: 0925-5710
Publisher: Springer Japan KK  
Date Published: 2012-08-01
Start Page: 164
End Page: 170
Language: English
DOI: 10.1007/s12185-012-1121-y
PROVIDER: scopus
PUBMED: 22791508
PMCID: PMC4052975
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84866990365&partnerID=40&md5=a4061aa7d123f8bcb2826706aa23721c
Notes: --- - "Export Date: 2 November 2012" - "CODEN: IJHEE" - "Source: Scopus"
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein
  2. Martin Stuart Tallman
    649 Tallman
Related MSK Work